BioWorld

July 7, 2006

View Archived Issues

MGI Sells Dacogen Rights Ex-North America To Cilag

Two months after receiving FDA approval for Dacogen to treat myelodysplastic syndromes, MGI Pharma Inc. licensed rights to the drug outside North America to Cilag GmbH. (BioWorld Today) Read More

Alnylam's Amended Merck Deal Worth Up To $120M In Payments

Read More

Tethers, Combination Therapy Suggest T-Cell Use In Cancer

Read More

Valera Seeking Approval For Annual Implant To Fight CPP

Read More

Ambrx's Series C Adds $52M To Advance Lead Candidates

Read More

Clinic Roundup

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More